Berita Kesehatan
Reduced moxifloxacin exposure in patients with tuberculosis and diabetes
Kamis, 02 Mei 2019 16:52:13

Bart G.J. DekkersMathieu S. BolhuisLies ter BeekWiel C.M. de LangeTjip S. van der WerfJan-Willem C. AlffenaarOnno W. Akkerman

European Respiratory Journal 2019; DOI: 10.1183/13993003.00373-2019

Extract

Prevalence of diabetes mellitus (DM) in patients with tuberculosis is increasing and may negatively impact outcome in patients with active disease [1]. Gastrointestinal problems, including gastroparesis, may result in delayed drug absorption or malabsorption in patients with DM, which may cause suboptimal drug exposure and poor outcome [2]. Studies on the pharmacokinetics of the first-line anti-tuberculosis drugs in patients with DM yielded conflicting results on low drug exposure [3–7]. Moxifloxacin is a potent bactericidal drug against Mycobacterium tuberculosis and is key for the treatment of multidrug-resistant tuberculosis (MDR-TB) [8]. Moreover, moxifloxacin can be recommended for tuberculosis treatment in patients with monoresistance or intolerance to first-line drugs [9]. Recently, we reported on a patient with tuberculosis and DM in which moxifloxacin exposure was reduced [10].

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Bolhuis has nothing to disclose.

Conflict of interest: Dr. ter Beek has nothing to disclose.

Conflict of interest: Dr. de Lange has nothing to disclose.

Conflict of interest: Dr. van der Werf has nothing to disclose.

Conflict of interest: Dr. Alffenaar has nothing to disclose.

Conflict of interest: Dr. Akkerman has nothing to disclose.

Conflict of interest: Dr. Dekkers has nothing to disclose.